BrightAccountsProduction v1.0.0 v1.0.0 2024-04-10 The company was not dormant during the period The company was trading for the entire period Unaudited Accounts Business and domestic software development 8 January 2026 0 15632274 2025-04-30 15632274 2024-04-09 15632274 2024-04-10 2025-04-30 15632274 uk-bus:PrivateLimitedCompanyLtd 2024-04-10 2025-04-30 15632274 uk-curr:Euro 2024-04-10 2025-04-30 15632274 uk-bus:SmallCompaniesRegimeForAccounts 2024-04-10 2025-04-30 15632274 uk-bus:FullAccounts 2024-04-10 2025-04-30 15632274 uk-bus:Director1 2024-04-10 2025-04-30 15632274 uk-bus:RegisteredOffice 2024-04-10 2025-04-30 15632274 uk-core:ShareCapital 2025-04-30 15632274 uk-core:SharePremium 2025-04-30 15632274 uk-core:RetainedEarningsAccumulatedLosses 2025-04-30 15632274 uk-core:TotalEquityAttributableToOwnersParentBeforeNon-controllingInterests 2025-04-30 15632274 uk-bus:FRS102 2024-04-10 2025-04-30 15632274 uk-core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2024-04-10 2025-04-30 15632274 uk-core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2025-04-30 15632274 uk-core:AdditionsToInvestments 2025-04-30 15632274 uk-core:CostValuation 2025-04-30 15632274 uk-core:CurrentFinancialInstruments 2025-04-30 15632274 2024-04-10 2025-04-30 15632274 uk-bus:AuditExempt-NoAccountantsReport 2024-04-10 2025-04-30 xbrli:pure iso4217:EUR xbrli:shares
Company Registration Number: 15632274
 
 
MEDICAL SOFTWARE TECHNOLOGIES LTD
 
Unaudited Financial Statements
 
for the financial period from 10 April 2024 (date of incorporation) to 30 April 2025
MEDICAL SOFTWARE TECHNOLOGIES LTD
DIRECTOR AND OTHER INFORMATION

 
Director Mr Alex Smotlak (Appointed 10 April 2024)
 
 
Company Registration Number 15632274
 
 
Registered Office and Business Address 10-12 Bourlet  Close
London
W1W 7BR
United Kingdom



MEDICAL SOFTWARE TECHNOLOGIES LTD
Company Registration Number: 15632274
BALANCE SHEET
as at 30 April 2025

Apr 25
Notes €
 
Fixed Assets
Intangible assets 6 38,663
Investments 7 10,000
─────────
Fixed Assets 48,663
─────────
 
Current Assets
Debtors 8 11,190
Cash and cash equivalents 2,456
─────────
13,646
─────────
─────────
Net Current Assets 13,646
─────────
Total Assets less Current Liabilities 62,309
═════════
 
Capital and Reserves
Called up share capital 3,788
Share premium account 9 97,537
Retained earnings (39,016)
─────────
Equity attributable to owners of the company 62,309
═════════
 
The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A (Small Entities).
       
The company has taken advantage of the exemption under section 444 not to file the Profit and Loss Account and Director's Report.
       
For the financial period from 10 April 2024 (date of incorporation) to 30 April 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006.
       
The director confirms that the members have not required the company to obtain an audit of its financial statements for the financial period in question in accordance with section 476 of the Companies Act 2006.
       
The director acknowledges his responsibilities for ensuring that the company keeps accounting records which comply with section 386 and for preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial period and of its profit and loss for the financial period in accordance with the requirements of sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.
       
Approved by the Director and authorised for issue on 8 January 2026
       
       
________________________________      
Mr Alex Smotlak      
Director      
       



MEDICAL SOFTWARE TECHNOLOGIES LTD
NOTES TO THE FINANCIAL STATEMENTS
for the financial period from 10 April 2024 (date of incorporation) to 30 April 2025

   
1. General Information
 
MEDICAL SOFTWARE TECHNOLOGIES LTD is a company limited by shares incorporated and registered in England. The registered number of the company is 15632274. The registered office of the company is 10-12 Bourlet  Close, London, W1W 7BR, United Kingdom which is also the principal place of business of the company. Business and domestic software development The financial statements have been presented in Euro (€) which is also the functional currency of the company.
         
2. Summary of Significant Accounting Policies
 
The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.
 
Statement of compliance
The financial statements of the company for the financial period ended 30 April 2025 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2006.
 
Basis of preparation
The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets.
 
Intangible assets
Intangible assets are valued at cost less accumulated amortisation.
 
Investments
Investments held as fixed assets are stated at cost less provision for any permanent diminution in value. Income from other investments together with any related tax credit is recognised in the Profit and Loss Account in the financial period in which it is receivable.
 
Trade and other debtors
Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.
 
Employee benefits
The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund. The company also operates a defined benefit pension scheme for its employees providing benefits based on final pensionable pay. The assets of this scheme are also held separately from those of the company, being invested with pension fund managers.
 
Taxation and deferred taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial period and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the Balance Sheet date.
 
Foreign currencies
Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the Balance Sheet date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated at the rates of exchange ruling at the date of the transaction. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. The resulting exchange differences are dealt with in the Profit and Loss Account.
 
Research and development
Development expenditure is written off in the same financial period unless the director are satisfied as to the technical, commercial and financial viability of individual projects. In this situation, the expenditure is deferred and amortised over the period from which the company is expected to benefit.
 
Ordinary share capital
The ordinary share capital of the company is presented as equity.
   
3. Period of financial statements
 
The financial statements are for the 12 month 21 days period from 10 April 2024 (date of incorporation) to 30 April 2025.
   
4. Statement on previous periods
 
The company did not present financial statements for previous periods.
     
5. Employees
 
The average monthly number of employees, including director, during the financial period was 0.
     
6. Intangible assets
  Development
  Costs
  €
Cost
At 10 April 2024 -
Additions 38,663
  ─────────
At 30 April 2025 38,663
  ─────────
Net book value
At 30 April 2025 38,663
  ═════════
 
During the period the company purchased a Patent.
       
7. Investments
  Group and Total
  participating  
  interests/  
  joint ventures  
Investments € €
Cost
Additions 10,000 10,000
  ───────── ─────────
At 30 April 2025 10,000 10,000
  ───────── ─────────
Net book value
At 30 April 2025 10,000 10,000
  ═════════ ═════════
     
8. Debtors Apr 25
  €
 
Amounts owed by related parties 10,000
Other debtors 1,190
  ─────────
  11,190
  ═════════
   
9. Reserves
 
Share Premium Reserve
 
The amount carried forward is the premium that arose from the issue of shares during the period.
 
     
10. Capital commitments
 
The company had no material capital commitments at the financial period-ended 30 April 2025.
         
11. Related party transactions
The company has availed of the exemption under FRS 102 Section 1A in relation to the disclosure of transactions with group undertakings.
   
12. Post-Balance Sheet Events
 
There have been no significant events affecting the company since the financial period-end.